The multicenter, open label, dose-ranging study will evaluate the effectiveness of SPI-2012 in comparison to a fixed and standard dose of Amgen Inc.’s (AMGN) Neulasta (pegfilgrastim) as a concurrent ...
As 2012 nears its end, the rear-view mirror is full of ups and downs in the health care sector. One company that had plenty of both is small-cap Spectrum Pharmaceuticals. Here are the major milestones ...
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology ...
Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for t
HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in ...
The Fool looks back at 2012 for up-and-down Spectrum Pharmaceuticals. All about Allos What was the biggest development for Spectrum in 2012? The acquisition of Allos Therapeutics ranks at the top of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results